GSK has agreed to acquire Rapt Therapeutics, a US-based biotech whose leading drug combats food allergies, in a deal that ...
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...
GSK has agreed to acquire RAPT Therapeutics, adding food allergy drug candidates to its pipeline. The company has received ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
The Daily Overview on MSN
GSK grabs RAPT for $2.2B in big bet on food allergy drugs
GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen on the side of an office building in Poznan, Poland. (Getty Images) This story was originally published on ...
We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) is one of the largest pharmaceutical companies in the world. The firm scored ...
About 1.8 million people used one or more of the 15 drugs through Medicare Part D or Part B between November 2024 and October 2025, the CMS said. The batch of 15 meds accounted for about $27 billion ...
A type 1 diabetes drug under development by GlaxoSmithKline has failed in late stage clinical trials. GSK (NYSE:GSK) announced Friday that otelixizumab, an investigational compound for type 1 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results